source
- MimiVax and Roswell Park start Phase 2 trial of SurVaxM with temozolomide for metastatic neuroendocrine tumorsMimiVax Inc. and Roswell Park Comprehensive Cancer Center announced the launch of a randomized Phase 2 study evaluating SurVaxM in combination with temozolomide for patients with progressing metast…
- Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCLRituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.